The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes
Abstract
We have studied the complement-activating properties of liposomes. We show that surface charge is a key determinant of complement-activating liposomes. The nature of the charge, whether negative or positive, appears to dictate which pathway of the complement system is activated. Phosphatidylcholine:cholesterol (PC:CHOL, 55:45 mol/mol) liposomes were made to exhibit a positive or negative surface charge by the addition of cationic or anionic lipids, respectively. Normal human or guinea pig serum was incubated with liposomes, followed by determining the residual hemolytic activity of the serum as a measure of complement activation. Negatively charged liposomes containing phosphatidyl-glycerol, phosphatidic acid, cardiolipin, phosphatidylinositol, or phosphatidylserine activated complement in a Ca(2+)-dependent manner suggesting activation occurred via the classical pathway. Positively charged liposomes containing stearylamine or 1,2-bis(oleoyloxy)-3-(trimethylammonio)propane activated complement via the alternative pathway. Neutral liposomes, PC:CHOL (55:45) and PC:CHOL:dipalmitoylphosphatidylethanolamine (35:45:20), failed to activate complement as measured by the hemolytic assays. We show that unsaturated liposomes are more potent complement activators than saturated liposomes and that 45 mol% cholesterol promotes complement protein-liposome interactions. Immunoblot analysis of phosphatidylglycerol-containing liposomes showed that C3b and C9 were associated with these liposomes. Thus, the complement consumption measured in the hemolytic assays represents active cleavage of the complement components and not passive adsorption to the liposome surface. These studies suggest that membranes composed of net charged phospholipids can activate the complement system. This observation underlines the importance in biologic membranes of complement regulatory proteins that protect normal cells from complement attack.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Large unilamellar liposomes with low uptake into the reticuloendothelial system
Allen, T. M., & Chonn, A. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80506-9 · Cited by 729
Self-citationGiclas, P. C., Ginsberg, M. H., & Cooper, N. R. (1979) · Journal of Clinical Investigation · doi:10.1172/jci109360 · Cited by 69
Cited by
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Interplay between inflammation and thrombosis in cardiovascular pathology
Stark, K., & Massberg, S. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00552-1 · Cited by 1,033
Parameters influencing the stealthiness of colloidal drug delivery systems
Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J.-P. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.039 · Cited by 740
Biodistribution and delivery efficiency of unmodified tumor-derived exosomes
Smyth, T., Kullberg, M., Malik, N., Smith-Jones, P., Graner, M. W., & Anchordoquy, T. J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.013 · Cited by 722
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 606
Plank, C., Mechtler, K., Szoka, F. C., & Wagner, E. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.12-1437 · Cited by 583
Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective
Moghimi, S. M., Hunter, A. C., & Andresen, T. L. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134623 · Cited by 545
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 503
Self-citationInteractions of nanomaterials and biological systems: Implications to personalized nanomedicine
Zhang, X.-Q., Xu, X., Bertrand, N., Pridgen, E., Swami, A., & Farokhzad, O. C. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.005 · Cited by 487
Current status of pH-sensitive liposomes in drug delivery
Drummond, D. C., Zignani, M., & Leroux, J.-C. (2000) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00011-4 · Cited by 477
Chonn, A., Semple, S. C., & Cullis, P. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37026-7 · Cited by 460
Self-citationSzebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Semple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Self-citationFilion, M. C., & Phillips, N. C. (1997) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(97)00126-0 · Cited by 428
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Semple, S. C., Chonn, A., & Cullis, P. R. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00128-2 · Cited by 402
Self-citationImmunological and Toxicological Considerations for the Design of Liposomes
Inglut, C. T., Sorrin, A. J., Kuruppu, T., Vig, S., Cicalo, J., Ahmad, H., & Huang, H.-C. (2020) · Nanomaterials · doi:10.3390/nano10020190 · Cited by 371
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Self-citationMosqueira, V. C. F., Legrand, P., Gulik, A., Bourdon, O., Gref, R., Labarre, D., & Barratt, G. (2001) · Biomaterials · doi:10.1016/s0142-9612(01)00043-6 · Cited by 325
Surface Engineering of Liposomes for Stealth Behavior
Nag, O., & Awasthi, V. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5040542 · Cited by 322
Allen, T. M. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90016-7 · Cited by 321
Platelet microparticles: a wide-angle perspective
Horstman, L. L., & Ahn, Y. S. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00044-4 · Cited by 300
Liposome: composition, characterisation, preparation, and recent innovation in clinical applications
Ahmed, K. S., Hussein, S. A., Ali, A. H., Korma, S. A., Lipeng, Q., & Jinghua, C. (2019) · Journal of Drug Targeting · doi:10.1080/1061186x.2018.1527337 · Cited by 294
C1q, Autoimmunity and Apoptosis
BOTTO, M. (2002) · Immunobiology · doi:10.1078/0171-2985-00141 · Cited by 289
Noninvasive Ultrasound Imaging of Inflammation Using Microbubbles Targeted to Activated Leukocytes
Lindner, J. R., Song, J., Xu, F., Klibanov, A. L., Singbartl, K., Ley, K., & Kaul, S. (2000) · Circulation · doi:10.1161/01.cir.102.22.2745 · Cited by 286
Morishita, M., Takahashi, Y., Nishikawa, M., Sano, K., Kato, K., Yamashita, T., Imai, T., Saji, H., & Takakura, Y. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24251 · Cited by 285
Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 283
Wagner, E., Curiel, D., & Cotten, M. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90008-6 · Cited by 275
Material properties in complement activation
Moghimi, S. M., Andersen, A. J., Ahmadvand, D., Wibroe, P. P., Andresen, T. L., & Hunter, A. C. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.002 · Cited by 268
Liposome and immune system interplay: Challenges and potentials
Zahednezhad, F., Saadat, M., Valizadeh, H., Zakeri-Milani, P., & Baradaran, B. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.030 · Cited by 267
Nanoparticle–aptamer bioconjugates for cancer targeting
Farokhzad, O. C., Karp, J. M., & Langer, R. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.3.311 · Cited by 256
The impact of protein corona on the biological behavior of targeting nanomedicines
Farshbaf, M., Valizadeh, H., Panahi, Y., Fatahi, Y., Chen, M., Zarebkohan, A., & Gao, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121458 · Cited by 95
Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine
Perche, F., Clemençon, R., Schulze, K., Ebensen, T., Guzmán, C. A., & Pichon, C. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.07.014 · Cited by 55
“Neutral nanoparticles show negligible protein adsorption and decreased complement activation compared to positive and negative ones.(40,42,45) Combined with PEGylation of the liposomes, the neutral surface is expected to extend blood circulation and increase the chances of nanoparticle retention in the desired organs…”
BackgroundNanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems
Grabrucker, A. M., Chhabra, R., Belletti, D., Forni, F., Vandelli, M. A., Ruozi, B., & Tosi, G. (2013) · Topics in Medicinal Chemistry · doi:10.1007/7355_2013_22 · Cited by 53
Metadata
- Authors
- Chonn, A., Cullis, P. R., & Devine, D. V.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-06
- Volume
- 146
- Issue
- 12
- Pages
- 4234-4241
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1512179335
- Cited by
- 367
- References
- 2
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.